Lashgari NA, Roudsari NM, Momtaz S, Abdolghaffari AH. Mammalian target of rapamycin-novel insight for management of inflammatory bowel diseases. World J Pharmacol 2022; 11(1): 1-5 [DOI: 10.5497/wjp.v11.i1.1]
Corresponding Author of This Article
Amir Hossein Abdolghaffari, PhD, Assistant Professor, Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, No. 99, Yakhchal, Gholhak, Shariati St., Tehran 1941933111, Iran. amirhosein172@hotmail.com
Research Domain of This Article
Pharmacology & Pharmacy
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Pharmacol. Jan 28, 2022; 11(1): 1-5 Published online Jan 28, 2022. doi: 10.5497/wjp.v11.i1.1
Mammalian target of rapamycin-novel insight for management of inflammatory bowel diseases
Naser-Aldin Lashgari, Nazanin Momeni Roudsari, Saeideh Momtaz, Amir Hossein Abdolghaffari
Naser-Aldin Lashgari, Nazanin Momeni Roudsari, Amir Hossein Abdolghaffari, Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran 1941933111, Iran
Saeideh Momtaz, Amir Hossein Abdolghaffari, Department of Pharmacology, Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, Karaj 1417614411, Iran
Saeideh Momtaz, Amir Hossein Abdolghaffari, Toxicology and Diseases Group (TDG), Pharmaceutical Sciences Research Center (PSRC), The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran 1941933111, Iran
Saeideh Momtaz, Amir Hossein Abdolghaffari, Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran 1941933111, Iran
Saeideh Momtaz, Amir Hossein Abdolghaffari, Gastrointestinal Pharmacology Interest Group (GPIG), Universal Scientific Education and Research Network (USERN), Tehran 1941933111, Iran
Author contributions: Lashgari NA, Roudsari NM and Momtaz S performed the collection and/or assembly of data and interpretation, manuscript writing; Abdolghaffari AH and Momtaz S performed the provision of study material, conception and design, and final approval of manuscript; all the authors have read and approved the manuscript.
Conflict-of-interest statement: The authors have no conflicts of interest to disclose.
Corresponding author: Amir Hossein Abdolghaffari, PhD, Assistant Professor, Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, No. 99, Yakhchal, Gholhak, Shariati St., Tehran 1941933111, Iran. amirhosein172@hotmail.com
Received: March 25, 2021 Peer-review started: March 25, 2021 First decision: July 27, 2021 Revised: August 11, 2021 Accepted: January 11, 2022 Article in press: January 11, 2022 Published online: January 28, 2022 Processing time: 305 Days and 22.4 Hours
Abstract
Inflammatory bowel diseases (IBDs), with blurred etiology, show a rising trend and are of global concern. Of various factors involved in IBD pathogenesis and development, inflammation has been shown to play a major role. Recognition of the molecular and cellular pathways that induce IBD is an emerging subject to develop targeted therapies. Mammalian target of rapamycin (mTOR) is one the most common receptors of many inflammatory pathways, including that of IBD. To this end, we intend to overview the mTOR inhibitors for their possible efficacy in present and future approaches to treatment of IBD.
Core tip: Inflammation is the main participant in the pathogenesis and development of inflammatory bowel disease (IBD). Since the mammalian target of rapamycin (mTOR) pathways are suggested to be involved in IBD progression, inhibition of the mTOR signaling may lead to a novel treatment modality for patients with IBD. Several biologics and synthetic and natural compounds have been introduced as mTOR inhibitors, which may control or eradicate intestinal inflammatory conditions such as IBD.
